Maxalt-Mlt (rizatriptan benzoate) NDC 78206-143

NDC codes

FDA NDC Directory

Product NDC (as listed)78206-143Labeler and product segments. Claims need a package NDC.

Product NDC at billing width78206-0143Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
78206-143-01	78206014301	6 CONTAINER in 1 CARTON (78206-143-01) / 3 POUCH in 1 CONTAINER / 1 BLISTER PACK in 1 POUCH (78206-143-99) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Jun 1, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Maxalt-Mlt
Generic name (nonproprietary): rizatriptan benzoate
Active ingredients: Rizatriptan benzoate — 10 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Organon LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020865
Marketing start: Jun 1, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 78206-143_47257235-a46d-4fee-a29d-08f8ba8e46c2SPL ID 47257235-a46d-4fee-a29d-08f8ba8e46c2SPL set ID 007b4644-e0e7-4863-9ae3-fe09676b3f5fRxCUI 213322, 312837, 314209, 828537UNII WR978S7QHH
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N478206014301 followed by a unit qualifier and the quantity

Package 78206-0143-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 29, 2026.

Indications (excerpt from the label)

MAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)